FIELD: chemistry; medicine.
SUBSTANCE: invention relates to dihydrochloride of N-(3-((5-ethoxy-1H-benzo[d]imidazol-2-yl)thio)alkyl)adamantylamine of general formula 1, where n can have value 2 or 3, R is H or CH3.
EFFECT: obtaining alternative compounds having antiparkinsonian activity and capable of reducing the intensity of comorbid conditions and side effects of Levodopa.
6 cl, 1 dwg, 18 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
INJECTABLE DOSAGE FORM FOR TREATMENT OF PARKINSON'S DISEASE, METHOD FOR PREPARING AND USING IT | 2011 |
|
RU2520758C2 |
AGENT FOR PREVENTION AND CORRECTION OF MOTOR, EXTRAPYRAMIDAL DISTURBANCES INDUCED BY NEUROLEPTICS | 2009 |
|
RU2421222C2 |
AGENT FOR TREATMENT AND PREVENTION OF PARKINSON'S DISEASE | 2006 |
|
RU2324492C1 |
BIOLOGICALLY ACTIVE HETEROGLYCOSIDE FOR CORRECTION OF PATHOLOGICAL STATES OF CENTRAL NERVOUS SYSTEM | 2006 |
|
RU2335289C2 |
MEDICATION FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2418577C1 |
PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING CHRONIC FATIGUE SYNDROME DUE TO ITS APPLICATION | 2003 |
|
RU2267319C2 |
2-METHOXY-4[(3aR,7aS)-3,3,6-TRIMETHYL-1,3,3a,4,5,7a-HEXAHYDRO-2-BENZOFURAN-1-YL]PHENOL - NOVEL AGENT FOR TREATING PARKINSON'S DISEASE | 2010 |
|
RU2436782C1 |
PSYCHOTIC DISORDER SIMULATION METHOD | 2004 |
|
RU2366464C2 |
METHOD OF PARKINSON DISEASE TREATMENT | 1994 |
|
RU2057529C1 |
ANTIDEPRESSANT FOR CORRECTION OF SIDE EFFECTS FROM NEUROLEPTICS | 2019 |
|
RU2746012C2 |
Authors
Dates
2024-06-03—Published
2023-07-06—Filed